NCT06567080View on ClinicalTrials.gov

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2027

Conditions
B-cell TumorsAutoimmune DiseasesLupus Erythematosus, SystemicLarge B-cell Lymphoma
Interventions
BIOLOGICAL

JWCAR201

JWCAR201 is a autologous CAR-T targeting CD19/CD20

Trial Locations (1)

200001

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY

lead

RenJi Hospital

OTHER

NCT06567080 - JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases | Biotech Hunter | Biotech Hunter